natgillin/translations-raw huggingface dataset:
Lincocin 40% Lincomycin (som lincomycinhydrochlorid) 
Lincocin 40% Lincomycin (as lincomycin hydrochloride)
Det er påvist, at Lincocin er effektivt til behandling og metafylakse af enzootisk pneumoni forårsaget af M. hyopneumoniae hos svin. 
Lincocin has been shown to be efficacious for the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae in pigs.
De fremlagte kliniske data viste, at Lincocin var effektivt til behandling og metafylakse af nekrotisk enteritis forårsaget af C. perfringens i en dosis på 5 mg lincomycin pr. kg kropsvægt i 7 på hinanden følgende dage. 
The provided clinical data demonstrated that Lincocin was effective in the treatment and metaphylaxis of necrotic enteritis caused by C. perfringens at a dose rate of 5 mg lincomycin per kg of body weight for 7 consecutive days.
De fremlagte kliniske data viste, at Lincocin var effektivt til behandling og metafylakse af enzootisk pneumoni forårsaget af M. hyopneumoniae, når det blev administreret i en dosis på 10 mg lincomycin pr. kg kropsvægt i 21 på hinanden følgende dage. 
The provided clinical data demonstrated that Lincocin was effective in the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae when administered at 10 mg lincomycin per kg of body weight for 21 consecutive days.
In vitro-dataene fra offentliggjort litteratur og fra indehaveren af markedsføringstilladelsens egen undersøgelse viste, at MIC-værdierne for lincomycin var brede og ikke var unimodale. 
The in vitro data from published literature and from the marketing authorisation holder's own study indicated that the MICs for lincomycin had wide ranges and were not unimodal.
Må ikke anvendes i tilfælde nedsat leverfunktion. 
Do not use in cases of hepatic dysfunction.
Må ikke blandes med lægemidler til dyr. 
Do not mix with any other veterinary medicinal product
Det er ligeledes dokumenteret, at Lincocin er effektivt til behandling og metafylakse af nekrotisk enteritis forårsaget af C. perfringens hos kyllinger. 
Lincocin has also been proven to be efficacious in the treatment and metaphylaxis of necrotic enteritis caused by C. perfringens in chickens.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Udfyldes nationalt. 
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER To be completed nationally
Behandlingen bør så vidt muligt baseres på lokale epidemiologiske oplysninger (på regionalt niveau, for det enkelte landbrug) om, hvordan enzootisk pneumoni/nekrotisk enteritis reagerer på behandling med lincomycin. 
Where possible, therapy should be based on local (regional, farm level) epidemiological information concerning the response of enzootic pneumonia/necrotic enteritis to treatment with lincomycin.
CVMP anerkendte, at det var vanskeligt at fastlægge en enkelt dosis og fastslog, at forslaget om en dosis på 5 mg lincomycin pr. kg kropsvægt i 7 dage var acceptabelt, selv om dosis var en smule vilkårligt valgt. 
The CVMP acknowledged the difficulties in determining a single dose and agreed that although somewhat arbitrarily selected, the proposal for a dose rate of 5 mg lincomycin per kg of body weight for 7 days is acceptable.
6.4 Særlige opbevaringsforhold 
SPECIAL STORAGE CONDITIONS
Silica, vandfri, kolloid Laktosemonohydrat 
Colloidal anhydrous silica Lactose monohydrate
• indbringelsen vedrørte harmoniseringen af produktresuméet, etiketteringen og indlægssedlen 
• the scope of the referral was the harmonisation of the summary of product characteristics, labelling and package leaflet;
Det dobbelte dosisinterval uden en klar vejledning til slutbrugeren om, hvornår lægemidlet skal administreres i henholdsvis den højeste og den laveste dosis, blev dog anset for at være uklart. 
It seemed to be in line with the posology assessed in the studies provided; however, the two-fold dose range with no clear guidance for the end-user as to when to administer the product at either the higher or lower limit of the range was considered to be ambiguous.
Til støtte for indikationen for behandling og metafylakse af enzootisk pneumoni forårsaget af Mycoplasma hyopneumoniae fremlagde indehaveren af markedsføringstilladelsen in vitrofølsomhedsdata, herunder en nylig intern undersøgelse, og kliniske data, herunder feltundersøgelser. 
In support of the indication for treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae the marketing authorisation holder provided in vitro susceptibility data, including a recent proprietary study, and clinical data, including field studies.
Svin og kyllinger 
Pigs and chickens
Der foreligger ældre undersøgelser foretaget med mikrobiologiske metoder, og de viser, at en tilbageholdelsestid på nul dage kunne være passende. 
Older studies, using microbiological methods, are available and indicate that a zero-day withdrawal period could be appropriate; however, these studies are not considered to have been conducted to current standards.
Ved gennemtrængning af tarmvæggen fordeles lincomycin i vidt omfang til alt væv, især lunger og ledhuler. 
Crossing the intestinal barrier, lincomycin is widely distributed to all tissues, especially the lungs and joint cavities; the volume of distribution is about 1 litre.
MARKEDSFØRINGSTILLADELSES NUMMER (NUMRE) Udfyldes nationalt. 
MARKETING AUTHORISATION NUMBER(S) To be completed nationally.
Zoetis Hungary Kft. 
Hungary Zoetis Hungary Kft. Budapest, Alkotás u.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Hvert g indeholder: 
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Behandling og metafylakse af enzootisk pneumoni forårsaget af Mycoplasma hyopneumoniae. 
Treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae.
Behandling og metafylakse af nekrotisk enteritis forårsaget af Clostridium perfringens. 
Treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens.
Svin, Fjerkræ (slagtekyllinger) 
Pigs, poultry (broilers)
Begrundelser for ændring af produktresuméet, etiketteringen og indlægssedlen 
Grounds for amendment of the summary of product characteristics, labelling and package leaflet
De pågældende undersøgelser blev dog foretaget i perioden 1977-1993, og MIC for isolaterne blev ikke bestemt i størstedelen af de fremlagte kliniske undersøgelser. 
The clinical data provided indicated that Lincocin was effective for the treatment of swine dysentery caused by B. hyodysenteriae; however, the studies in question were conducted in the period 1977-1993 and the MICs of isolates were not determined in the majority of clinical studies submitted.
Enzootisk pneumoni: 10 mg lincomycin pr. kg kropsvægt (svarende til 25 mg af lægemidlet pr. kg kropsvægt) i 21 på hinanden følgende dage. 
Enzootic pneumonia: 10 mg lincomycin per kg of body weight (corresponding to 25 mg product per kg bodyweight) for 21 consecutive days.
Nekrotisk enteritis: 5 mg lincomycin pr. kg kropsvægt (svarende til 12,5 mg af lægemidlet pr. kg kropsvægt) i 7 på hinanden følgende dage. 
Necrotic enteritis: 5 mg lincomycin per kg of body weight (corresponding to 12.5 mg product per kg bodyweight) for 7 consecutive days.
DYREARTER Svin og kyllinger. 
TARGET SPECIES Pigs and chickens.
• CVMP har gennemgået produktresuméet, etiketteringen og indlægssedlen som forelagt af indehaveren af markedsføringstilladelsen og taget alle de indsendte data i betragtning anbefalede CVMP ændringen af markedsføringstilladelserne for Lincocin og relaterede navne, jf. bilag I. Produktresumé, etikettering og indlægsseddel for disse fremgår af bilag III. 
the CVMP has recommended the amendment of the marketing authorisations for Lincocin and its associated names as referred in Annex I for which the summary of product characteristics, labelling and package leaflet are set out in Annex III.
2 dage efter behandlingens afslutning var restkoncentrationerne i lever, nyrer og muskler alle under MRL. Én sammensat muskelprøve ud af tre havde restkoncentrationer, der lå en smule over MRL (57 µg/kg i forhold til 50 µg/kg). 
One composite muscle sample out of three had residues slightly above the MRL (57 µg/kg versus 50 µg/kg).
INDIKATION(ER) Læs indlægssedlen inden brug. 
Read the package leaflet before use.
Pulver til anvendelse i drikkevand 
powder for use in drinking water
VETERINÆRLÆGEMIDLETS NAVN Lincocin 400 mg/g pulver til brug i drikkevand. 
NAME OF THE VETERINARY MEDICINAL PRODUCT Lincocin 400 mg/g powder for use in drinking water.
Farmakokinetiske oplysninger 
Pharmacokinetic particulars
• Måldyrearter 
• Target species
− Ikke almindelige (flere end 1, men færre end 10 dyr af 1.000 behandlede dyr) 
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Lincomycin (som lincomycinhydrochlorid) 400 mg 
Each g contains: Lincomycin (as lincomycin hydrochloride) 400 mg
Til anvendelse i drikkevand 
In drinking water use
Derfor bør brugen af lægemidlet ikke tillades til æglæggende fugle, som producerer æg til menneskeligt konsum. 
Not authorised for use in laying birds producing eggs for human consumption.
Til behandling og metafylakse (”gruppebehandling”) af nekrotisk enteritis forårsaget af Clostridium perfringens. 
For the treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens.
Lægemiddelform Dyrearter 
Animal species
EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF UBRUGTE LÆGEMIDLER ELLER AFFALD FRA SÅDANNE 
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
Begge kan forårsage allergiske reaktioner hos nogle personer. 
This product contains lincomycin and lactose monohydrate, either of which can cause allergic reactions in some people.
Der kan forekomme antagonisme mellem lincomycin og macrolider som f.eks. erythromycin og andre bakteriedræbende antibiotika. 
Antagonism may exist between lincomycin and macrolides such as erythromycin and other bactericidal antibiotics; concurrent use is therefore not recommended due to competitive binding at the 50S ribosomal subunit of the bacterial cell.
INDLÆGSSEDDEL Lincocin 400 mg/g pulver til brug i drikkevand 
PACKAGE LEAFLET: Lincocin 400 mg/g powder for use in drinking water
VETERINÆRLÆGEMIDLETS NAVN Lincocin 400 mg/g pulver til opløsning i drikkevand 
NAME OF THE VETERINARY MEDICINAL PRODUCT Lincocin 400 mg/g powder for use in drinking water
ANGIVELSE AF AKTIVE STOFFER Hvert gram indeholder 400 mg lincomycin (som lincomycinhydrochlorid). 
Lincocin 400 mg/g powder for use in drinking water Lincomycin (as lincomycin hydrochloride) STATEMENT OF ACTIVE SUBSTANCES Each g contains 400 mg lincomycin (as lincomycin hydrochloride).
Med hensyn til æglæggende høns er der ingen data til støtte for en tilbageholdelsestid for æg. 
Regarding laying hens, there are no data to support a withdrawal period in eggs; hence, the use of the product should not be authorised in laying birds producing eggs for human consumption.
− Meget sjældne (færre end 1 dyr ud af 10.000 behandlede dyr, herunder isolerede rapporter). 
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Oral til anvendelse i drikkevand 
Oral via the drinking water
Indehaver af markedsføringstilladelsen: Udfyldes nationalt. 
Manufacturer responsible for batch release: To be completed nationally
Indehaveren af markedsføringstilladelsen fremlagde in vitro-følsomhedsdata, herunder en nylig intern undersøgelse fra 2016, kliniske undersøgelser og data fra den videnskabelige litteratur, til støtte for den foreslåede harmoniserede indikation for behandling og metafylakse af nekrotisk enteritis forårsaget af Clostridium perfringens. 
To support the proposed harmonised indication for treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens, the marketing authorisation holder presented in vitro susceptibility data including a recent proprietary study from 2016, clinical studies and data from the scientific literature.
Svin, kyllinger Oral 
Pigs, chickens
Særlige forholdsregler, der skal træffes af personer, der administrerer lægemidlet til dyr: Produktet indeholder lincomycin og laktosemonohydrat. 
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Medlemsstaternes gennemførelse af standpunktet: 
Implementation of the position by the Member States:
26. juli 2019 
26 July 2019
26. juni 2019 
26 June 2019
Vedtagelse af CMDh's standpunkt ved konsensus: CMDh-mødet i maj 2019 Oversættelser af bilagene for indstillingen fremsendes til de nationale kompetente myndigheder: 
Transmission to National Competent Authorities of the translations of the annexes to the position:
Sjælden (forekommer hos færre end 1 ud af 1.000 patienter) 
Rare (affects less than 1 in 1,000 people)
Punkt 4.4 
Section 4.4
Vedtaget af PRAC d. 14.-17. marts 2016 
Adopted at the 14-17 March 2016 PRAC
Den øgede risiko synes at være relateret til behandlingens intensitet og varighed. 
The increased risk appears to be related to the degree and duration of immunosuppression.
Ny ordlyd af produktinformation - uddrag af PRAC's anbefalinger om signaler 
New product information wording - Extracts from PRAC recommendations on signals
Axitinib skal seponeres, hvis patienten udvikler nefrotisk syndrom. 
Axitinib should be discontinued if the patient develops nephrotic syndrome.
Bivirkninger, hvis hyppighed ikke kendes (kan ikke beregnes ud fra forhåndenværende data): 
Not known side effects are (frequency cannot be estimated from the available data):
• Lavt indhold af fibrinogen i blodet (et protein, der medvirker til blodets størkning) 
• Low fibrinogen levels in the blood (a protein involved in blood clotting)
• tumorer, herunder hudkræft. 
• tumours, including skin cancer.
Indlægsseddel: Det er ikke nødvendigt at foretage ændringer i indlægssedlen. 
Package Leaflet (PL) No changes to the PL are needed.
Mutagenicitet og karcinogenicitet 
Mutagenicity and carcinogenicity/Carcinogenicity
Punkt 4.8 Bivirkninger 
4.8 Undesirable effects
• forskellige former for kræft, herunder blodkræft, lymfekræft og hudkræft 
• various types of cancers including blood, lymph and skin cancers
Når <De> <du> tager {X}, skal <De> <du> derfor undgå for megen eksponering for sollys, og <De> <du> skal bruge beskyttende påklædning og solcreme med en høj beskyttelsesfaktor. 
Therefore, when taking <X>, avoid excessive exposure to sunlight, wear protective clothing and use protective sunscreen with a high protection factor.
Behandling med {X} kan medføre en øget risiko for: 
Taking <X> could put you at greater risk of:
Det anbefales at monitorere for proteinuri før og regelmæssigt under behandlingen med axitinib. 
Monitoring for proteinuria before initiation of, and periodically throughout, treatment with axitinib is recommended.
Ikke kendt (kan ikke estimeres ud fra forhåndenværende data): hypofibrinogenæmi 
Frequency not known (cannot be estimated from the available data): hypofibrinogenaemia
Det er rapporteret, at seponering af den immunsupprimerende behandling kan medføre partiel regression af den lymfoproliferative sygdom. 
It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.
Hvis MAS opstår eller mistænkes, skal evaluering og behandling startes så hurtigt som muligt, og mercaptopurin skal seponeres. 
If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with mercaptopurine should be discontinued.
• lymfoproliferative sygdomme o behandling med {X} øger risikoen for at få en type kræft, der kaldes "lymfoproliferativ sygdom". 
• lymphoproliferative disorders o treatment with <X> increases your risk of getting a type of cancer called lymphoproliferative disorder.
Hvis MAS opstår eller mistænkes, skal evaluering og behandling startes så hurtigt som muligt, og azathioprin skal seponeres. 
If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with azathioprine should be discontinued.
Ved behandlingsregimer, der består af flere immunsupprimerende lægemidler, herunder thiopuriner, kan dette medføre dødsfald. 
With treatment regimen containing multiple immunosuppressants (including thiopurines), this may lead to death.
Hos patienter, der udvikler moderat til svær proteinuri, skal dosis reduceres eller behandlingen afbrydes midlertidigt (se pkt. 
For patients who develop moderate to severe proteinuria, reduce the dose or temporarily interrupt axitinib treatment (see section 4.2).
Læger skal være opmærksomme på symptomer på infektion forårsaget af f.eks. Epstein-Barr-virus (EBV) og cytomegalovirus (CMV), da disse kan udløse MAS. 
Physicians should be attentive to symptoms of infection such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS.
Mercaptopurin (Xaluprine); azathioprinlymfoproliferative sygdomme (EPITT nr. 18503) 
Mercaptopurine (XALUPRINE); azathioprineLymphoproliferative disorders (EPITT no 18503)
Et behandlingsregime bestående af flere immunsuppressiva, herunder thiopuriner, bør derfor anvendes med forsigtighed, da det kan medføre lymfoproliferative sygdomme, i nogle tilfælde med dødelig udgang. 
A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities.
Patienter i immunsupprimerende behandling, herunder med <azathioprin> <mercaptopurin>, har en øget risiko for at udvikle lymfoproliferative sygdomme og andre maligniteter, især hudcancer (melanom og non-melanom), sarkomer (Kaposi og non-Kaposi) og cervixcancer in situ. 
Patients receiving immunosuppressive therapy, including <azathioprine> <mercaptopurine> are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ.
Det skal <De> <du> vide, før <De> <du> begynder at <tage> <bruge> {X} Advarsler og forsigtighedsregler Kontakt lægen<,> <eller> <apotekspersonalet> <eller sundhedspersonalet>, før <De> <du> <tager> <bruger> {X}. 
What you need to know before you <take> <use> X Warnings and precautions Talk to your doctor <or> <pharmacist> <or nurse> before <taking> <using> X If you are receiving immunosuppressive therapy, taking <X> could put you at greater risk of:
Indlægsseddel (mercaptopurin og azathioprin) 2. 
Package leaflet (mercaptopurine and azathioprine) 2.
En kombination af flere immunsuppressiva administreret samtidigt øger risikoen for EpsteinBarr-virus (EBV)-relaterede lymfoproliferative sygdomme. 
A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.
Produktresumé (mercaptopurin) 
Summary of Product Characteristics (mercaptopurine)
Makrofag-aktiveringssyndrom (MAS) er en kendt, livstruende tilstand, der kan udvikles hos patienter med autoimmune sygdomme, navnlig inflammatorisk tarmsygdom, og der kan potentielt være en øget følsomhed for udvikling af syndromet ved brug af azathioprin. 
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD), and there could potentially be an increased susceptibility for developing the condition with the use of azathioprine.
cyster og polypper) Sjældne bivirkninger: neoplasmer, herunder lymfoproliferative sygdomme, hudcancer (melanom og non-melanom), sarkomer (Kaposis og non-Kaposis) og cervixcancer in situ ... (se pkt. 
Rare: neoplasms including lymphoproliferative disorders, skin cancers (melanomas and nonmelanomas), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ…(see section
o En kombination af flere immunsupprimerende lægemidler, der gives samtidigt, øger risikoen for sygdomme i lymfesystemet på grund af en virusinfektion (Epstein-Barr-virus-relaterede lymfoproliferative sygdomme). 
o A combination of multiple immunosuppressants, given concomitantly increases the risk of disorders of the lymph system due to a viral infection (Epstein-Barr virus (EBV)-associated lymphoproliferative disorders).
Der er rapporteret proteinuri, herunder grad 3- og 4-proteinuri, i kliniske studier med axitinib (se pkt. 
In clinical studies with axitinib, proteinuria, including that of Grade 3 and 4 severity, was reported (see section 4.8).
Makrofag-aktiveringssyndrom (MAS) er en kendt, livstruende tilstand, der kan udvikles hos patienter med autoimmune sygdomme, navnlig inflammatorisk tarmsygdom (ikke-godkendt indikation), og der kan potentielt være en øget følsomhed for udvikling af syndromet ved brug af mercaptopurin. 
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD) (unlicensed indication), and there could potentially be an increased susceptibility for developing the condition with the use of mercaptopurine.
• udvikling af en alvorlig lidelse, der hedder makrofag-aktiveringssyndrom (kraftig aktivering af hvide blodlegemer forbundet med en betændelseslignende reaktion (inflammation)). 
• developing a serious condition called Macrophage Activation Syndrome (excessive activation of white blood cells associated with inflammation), which usually occurs in people who have certain types of arthritis
Produktresumé (azathioprin) 
Summary of Product Characteristics (azathioprine)
Tigecyclin (Tygacil) - hypofibrinogenæmi (EPITT nr. 18479) 
Tigecycline (TYGACIL) - Hypofibrinogenaemia (EPITT no
Axitinib (Inlyta) - nefrotisk syndrom (EPITT nr. 18484) 
Axitinib (INLYTA) - Nephrotic syndrome (EPITT no
Produktresumé 4.8 Bivirkninger Tabel over bivirkninger Blod og lymfesystem 
Blood and lymphatic system disorders
Disse omfatter blandt andet: 
These include, among others:
Dette lægemiddel kan udgøre en risiko for miljøet. 
This medicine may pose a risk for the environment.
* Der var rapporteret letale hændelser. 
* Fatal events were reported.
Ca. 90% af de inkluderede patienter i denne analyse var asiatere eller hvide. 
Approximately 90% of patients included in this analysis were Asian or White.
Din læge vil måske nedsætte din dosis af lægemidlet afhængigt af, hvor godt du tåler det. 
Your doctor may decrease the dose of your medicine depending on how well you tolerate it.
Data baseret på data cut-off-dato den 29. juli 2016. 
Data based on data cut-off date of 29 July 2016.
• Slug tabletten hel med et glas vand. 
• Swallow the tablet whole with a glass of water.
• Tag tabletten på omtrent samme tid hver dag. 
• Take the tablet at about the same time each day.
Det kan være nødvendigt at justere dosis baseret på individuel sikkerhed og tolerabilitet. 
Dose modifications may be required based on individual safety and tolerability.
Den statistiske signifikans af forbedringen af OS kunne således ikke bedømmes tilstrækkeligt. 
Therefore, the statistical significance of OS improvement could not be formally assessed.
Patienter skal opfordres til at tage deres dosis på omtrent samme tidspunkt hver dag. 
Patients should be encouraged to take their dose at approximately the same time each day.
Dosis (en gang dagligt) 
Dose (once daily)
Alder, race, køn og kropsvægt 
Age, race, gender, body weight
Anbefalet startdosis 
Recommended starting dose
Vizimpro er til oral anvendelse. 
Vizimpro is for oral use.
• Du kan tage tabletten sammen med eller uden mad. 
• You can take the tablet with or without meals.